Head And Neck Cancer Diagnostics| Market Size and Share Analysis and Competitive Landscape 2024-2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company presents an extensive market research report on the Head And Neck Cancer Diagnostics Global Market Report 2024, furnishing businesses with a competitive edge through a detailed examination of the market structure, encompassing estimates for various segments and sub-segments.

Furthermore, the report highlights on emerging trends, significant drivers, challenges, and opportunities, providing all necessary data for thriving in the industry. This report market research offers a comprehensive perspective, including an in-depth analysis of the present and future scenarios within the industry.

Market Sizing:

The head and neck cancer diagnostics market size has grown rapidly in recent years. It will grow from $1.51 billion in 2023 to $1.79 billion in 2024 at a compound annual growth rate (CAGR) of 18.4%. The growth in the historic period can be attributed to tobacco and alcohol consumption, increasing aging population, awareness campaigns, biopsy techniques development, healthcare infrastructure development.

The head and neck cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $3.32 billion in 2028 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to genomic biomarkers, rising incidence of hpv-related cancers, integration of artificial intelligence (ai), immunotherapy and targeted therapies, healthcare policy and reimbursement changes. Major trends in the forecast period include liquid biopsy dominance, multi-modality diagnostics, point-of-care diagnostics, global collaborations and partnerships, digital pathology integration.

Request for free sample report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12016&type=smp

Key Market Players:

Major companies operating in the head and neck cancer diagnostics market report are F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Co., Abbott Laboratories, Siemens Healthineers AG, BioNTech AG, Koninklijke Philips N.V., GE HealthCare Technologies Inc., Laboratory Corporation of America, Agilent Technologies Inc., Hologic Inc., Illumina Inc., Shimadzu Corporation, Sysmex Corp., Varian Medical Systems Inc., QIAGEN N.V., Exact Sciences Corp., Bio-Techne Corp., Carestream Health Inc., Myriad Genetics Inc., Cepheid Inc., Invitae Corporation, Accuray Inc., Canon Medical Systems Corporation, NanoString Technologies Inc, Asuragen Inc., Caris Life Sciences Inc., HTG Molecular Diagnostics Inc., Oncgnostics GmbH, Perseus Proteomics Inc., VolitionRx Ltd.

Market Drivers:

The increasing incidence of head and neck cancer is expected to propel the growth of the head and neck cancer diagnostics market going forward. Head and neck cancer is a group of tumors affecting the head and neck region's tissues and organs. These malignancies include the mouth, pharynx, larynx, salivary glands, nasal cavity, and sinuses. Head and neck cancer diagnostics help head and neck cancer patients diagnose the disease early with various tests, including an incisional biopsy and a barium swallow test. For instance, in February 2023, according to the American Society of Clinical Oncology, a US-based professional organization for physicians and oncology professionals, Head and neck cancer made up 4% of all malignancies in the US. Head and neck cancer is predicted to affect 66,920 people in the USA in 2023 (49,190 men and 17,730 women). In 2020, head and neck cancer will affect 562,328 people worldwide. Furthermore, according to head and neck cancer in Australia statistics, there were 5,189 new head and neck cancer cases in 2022. Therefore, the rise in head and neck cancer incidence is driving the growth of the head and neck cancer diagnostics market.

Learn More About The Market Report -
https://www.thebusinessresearchcompany.com/report/head-and-neck-cancer-diagnostics-global-market-report

The head and neck cancer diagnostics market covered in this report is segmented -

1) By Diagnostic Method: Diagnostic Imaging Equipment, Endoscopy Screening Equipment, Biopsy Screening Tests, Dental Diagnostic Methods, Other Diagnostic Methods
2) By Channel: Retail and Specialty Pharmacies, Hospital Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Diagnostic Centers, Other End Users

The report answers the following questions:
What are the primary factors propelling the market during the projected period?

In which region is the most substantial growth expected?

Which trend will take center stage in the upcoming period?

Want To Know More About The Business Research Company?

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.